Clinical Trial: Comparing Inclisiran Versus Statin for Primary Aldosteronism

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07884955) titled 'Comparing Inclisiran Versus Statin for Primary Aldosteronism' on Oct. 13.

Brief Summary: Primary aldosteronism represents one of the leading causes of resistant hypertension. Circulating cholesterol is established as the exclusive substrate for adrenal aldosterone synthesis, and statins, which suppress cholesterol production, are currently widely applied in clinical settings. Emerging clinical evidence has demonstrated that in patients with essential hypertension, the plasma aldosterone level decreased by 43% (from 13.9 ng/dL to 7.9 ng/dL) after treatment with PCSK9 inhibitors. However, the effect of PCSK9 inhibitors with superior l...